Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium lactis bb-12 + lactobacillus acidophilus la-5 + oligofructose
- Development stage
- Unknown
- Lead developer
- Chr. Hansen
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This is a combination probiotic and prebiotic supplement containing two well-characterized probiotic strains—Bifidobacterium animalis subsp. lactis BB-12 and Lactobacillus acidophilus LA-5—together with the prebiotic fiber oligofructose. The probiotics are live microorganisms that confer health benefits by modulating the gut microbiota, supporting gastrointestinal function, enhancing immune responses, and reducing inflammation. Oligofructose serves as a fermentable dietary fiber that selectively stimulates the growth of beneficial bacteria in the colon (prebiotic effect). Clinical studies have shown this combination can help alleviate chronic constipation, reduce antibiotic-associated diarrhea, improve symptoms in ulcerative colitis patients post-surgery, support restoration of gut microbiota after antibiotics or H. pylori eradication therapy, and may exert anti-inflammatory effects via modulation of TLR2-mediated NF-kB/MAPK signaling pathways[1][2][4][6][8]. The product is typically used as a dietary supplement for digestive health.
- Other names
- bifidobacterium animalis subsp. lactis bb-12 + lactobacillus acidophilus la-5 + oligofructosebifidobacterium lactis bb-12 and lactobacillus acidophilus la-5 with oligofructose
02
Targets
TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on bifidobacterium lactis bb-12 + lactobacillus acidophilus la-5 + oligofructose.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium lactis bb-12 + lactobacillus acidophilus la-5 + oligofructose.